Tuesday, April 22, 2014 6:03:36 AM
All hurting BORK holders agree that the status of this company, in regards to a near zero sales execution, is a direct result of the manner this company has been run by John Bourque when he was President and CEO, and then by others after he left the company.
"If [Kryron] was that good and profitable people would be knocking on the doors."
There has been two "good" announcements.
(1.) ... has earned NIJ certification for its Level III stand-alone Kryron Terminator Armor.
"good and profitable" - Before any established armor company knocks on our door, they need proof, to see sales and revenue. We had none, so no knocks willing to buy a pig in a poke.
(2.) Conclusion of Initial Independent Lab Testing of Kryron with Positive Results (thermal conductivity)
"good and profitable" - The testing done got a grade of D- for effort and results, resulting in failure for any knocking results.
"You could not have been saying that the way to go is more testing."
Actually that's a big yes, but in a manner totally different than all the testings and demos so far accomplished.
Potential door knockers need to know if the alloys created using the Kryron Process (the patents) are unique and unequaled from all currently existing alloy processes to create internal structures that have the potential to generate advanced properties of an alloy.
This test needs to be done, and if it shows that Kryron alloys deliver as promised, then our doors will be knocked down.
To this day that test has not been done in a manner to satisfy the engineering and science community whereupon reports of what this company has makes it into the journals that deal with this area. That needs to be accomplished before those engaged in the business of business and investing will take notice of this company and knock.
Doug
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM